Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 331

recruiting
3 987
countries
28
conditions
2 109

4 235 trials match your criteria

Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Burkitt's lymphoma+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Hairy cell leukaemia

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Hairy Cell Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mesna

Study on MK-7684A and Docetaxel for Treating Metastatic Non-Small Cell Lung Cancer in Patients After Platinum Chemotherapy and Immunotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Richter's syndrome

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Waldenstrom Macroglobulinemia Using a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Study on Atezolizumab, Bevacizumab, and Paclitaxel for Advanced Lung Cancer Patients After Immunotherapy and Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm

Not recruiting

Study of Olaparib for Patients with Advanced Cancer Having HRRm or HRD Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Study on the Safety and Effectiveness of Sacituzumab Govitecan for Patients with Triple Negative Metastatic Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan

Systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of CGT9486 for Patients with Nonadvanced Systemic Mastocytosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide

Study on Physical Activity and Joint Health in Patients Aged 12 and Older with Severe Hemophilia A Treated with Efanesoctocog Alfa for 24 Months

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.